Treatment of viral hepatitis (II). Treatment of chronic hepatitis C;Tratamiento de las hepatitis víricas (II). Tratamiento de la hepatitis crónica C

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 8, 2006, Pages 518-526

  Sánchez Quijano, Armando ^a   Lissen Otero, Eduardo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Chronic hepatitis; HCV; Treatment of Chronic Hepatitis C

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL ANALYSIS; DISEASE ASSOCIATION; ERADICATION THERAPY; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; SEROLOGY; VIRUS HEPATITIS;

EID: 33750983965     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13092470     Document Type: Article

References (53)

1. World Health Organization. Hepatitis C global prevalence. Weekly Epidemiological Record. 1997;72:341-8.
2. Global surveillance and control of hepatitis C. Report of a WHO consultation organized with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6:35-47.
3. World Health Organization. Hepatitis C global prevalence (update). Weeckly Epidemiological Record. 2000;3:18-9.
4. Alter MJ, Margolis HS, Krawczynski K, Jutson FN, Mares A, Alexander WJ, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med. 1992;327:1899-905.
5. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. Hepatology. 1997;26:485-90.
6. Schreiber GB, Bush MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996;334:1685-90.
7. Soto B, Rodrigo L, García-Bengoechea M, Sánchez-Quijano A, Riestra S, Arenas JI, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case: a multicentre study of 423 pairings. J Intern Med. 1994;236:515-9.
8. Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C, Kako M, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med. 1994; 330:744-50.
9. Sánchez-Quijano A, Abad MA, Torronteras R, Rey C, Pineda JA, Leal M, et al. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol. 1997;27:25-9.
10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825-32.
11. Seeff LB, Miller RN, Rabkin CS, Buskell-bales Z, Straley-Eason KD, Smoak BL, et al. 45-years follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105-11.
12. Massard J, Ratziu V, Thabut D, Mousalli J, Lebray P, Benhamou Y, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44:19-24.
13. Feld JJ, Liang TK. Hepatitis C - Identifying Patients with Progressive Liver Injury. Hepatology. 2006;43 Suppl 1:194-206.
14. Brechot C, Jaffredo F, Lagorce D, Gerken G, Meyer zum Buschenfelde K, Papakonstontinou A, et al. Impact of HBV, HCV and GBV/HGV on hepatocellular carcinomas in Europe. Results of a European concerted action. J Hepatol. 1998;29:173-83.
15. Centers for Disease Control and Prevention. Recommendations for prevention and control of Hepatitis C (HCV) Virus Infection and HCV related chronic disease. MMWR. 1998;47(RR-19):1-30.
16. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. June; 10-12,2002. Final Statement. Revisions made on September 12, 2002. Disponible en: http://consensus.nih. gov/2002/2002HepatitisC2002116html.htm Visitado el 6 de abril 2006.
17. Armstron GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-82.
18. Strader DB, Wright T, Thomas DL, Seef LB. AASLD Practice Guideline. Diagnosis, Management and Treatment of Hepatitis C. Hepatology. 2004;39: 1147-71.
19. National Hepatitis C Program Office Hepatitis C Technical Advisory Group. Department of Veterans Affairs. Treatment Recommendations for Patients with Chronic hepatitis C. September 2003. Version 5.0. Disponible en: http://www.hepatitis.va.gov/vahep?page = tp03-01-04-32. Visitado el 5 de abril de 2006.
20. Rockey DC, Bissel M. Noninvasive Mesasures of Liver Fibrosis. Hepatology. 2006;43:113-20.
21. Radkoski M, Gallegos-Orozco JE, Jablonska J, Colby TV, Walewsa-Zielecka B, Kubicka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41:106-14.
22. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-13.
23. th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, 2005; San Francisco, California. Abstract 1265.
24. th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, 2005; San Francisco, California. Abstract 85.
25. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirina plus interferon for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 1994;107:812-7.
26. McHutchison JG, Gordon SC, Schiff ER, Mitchell L, Lee Wm, Rutsgi VK, et al. Interferon alfa-2b alone or in combination with ribavirina as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-92.
27. Poynard T, Marcelli P, Lee S, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;353:1426-32.
28. Fried MW, Shiffman ML, Reddy KR, Smitch C, Marinos G, Goncales FL Jr, et al. Peginterferon alpha 2a plus ribavirina for chronic hepatitis C virus infection. N Engl J Med. 2002;347:976-82.
29. Manns MP, McHutchison JG, Gordon S, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-65.
30. Hadziyannis SJ, Sete H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. PEGASYS International Study Group. Peginterferon-alfa2a and Ribavirin Combination therapy in Chronic hepatitis C. A randomized Study of Treatment Duration and Ribavirin Dose. Ann Intern Med. 2004;140:346-55.
31. Mangia A, Santoro R, Minerva N, Ricci GL, Carreta V, Pérsico M, et al. Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 weeks in HCV Genotype 2 or 3. N Engl J Med. 2005;325:1609-17.
32. Hassanein TI, Cooksley G, Sulkowski M, Smith C, Marinos G, Lay MG, et al. The impact of peginterferon alpha-2a plus ribavirina combination therapy on health-quality of life in chronic hepatitis C. J Hepatol. 2004;40:675-83.
33. Alberti A, Benvegua L, Boccatoa A, Ferrria G. Natural History of Initially Mild Chronic hepatitis C. Dig Liver Dis. 2004;36:646-54.
34. EASL International Consensus Conference on Hepatitis C: Paris 26-28, February 1999, consensus statement. J Hepatol. 1999;30:956-61.
35. Lauer GM, Walker BD. Hepatitis C Virus Infection. N Engl J Med. 2001; 345:41-52.
36. Cecil BD, Lavelle M. Sustained viral response improves survival in patients with either compensated or decompensated hepatitis C. J Hepatol. 2005; 42 Suppl 2:A21.
37. Ahmed F, Jacobsen IM. Treatment of relapsers after combination therapy for chronic hepatitis. Infect Dis Clin North Am. 2006;20:37-53.
38. Sherman M, Yoshida E, Deschenes M, Kradjen M, Bain V, Peltekian K, et al. Peginterferon alfa-2a (40 kD) plus ribavirin in chronic hepatitis C patients who failed previous interferon-based therapy: results of a multicentre open-label expanded access program in Canada. J Hepatol. 2005;42 Suppl 2:A603.
39. Nevens F, Van Vlierberghe H, D'Heygere F, Delwaide J, Adler M, Henrion J, et al. Peginterferon alfa-2a (40 kD) plus ribavirin is as effective in patients relapsing after conventional interferon based therapy than in naive patients: results from the BERNAR-1 trial. J Hepatol. 2005;42:A588.
40. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. International Hepatitis Interventional theraphy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493-9.
41. Shiffman ML, Di Bisciglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and Ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126: 1015-23.
42. Poynard T, Schiff E, Terg R, Goncales M, Diago M, Reichen J, et al. Sustained virologic response (SVR) in the EPIC3 trial: week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving peg-intron/rebetol (PR) weight-based dosing (WBD). J Hepatol. 2005;42 Suppl 2:A96.
43. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutelier A, et al. Liver fibrosis progression in HIV-HCV coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-8.
44. Soto B, Sánchez-Quijano A, Rodrigo L, Del Olmo JA, García-Bengoechea M, Hernández-Quero J, et al. Humman immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
45. Salmon-Cerón D, Lewden C, Morlat P, Bevilacqua S, Jongla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C an B viruses and alcohol. J Hepatol. 2005;42:799-805.
46. Anderson KB, Guest JL, Rimland D. Hepatitis C virus co-infection increases mortality in HIV patients in the highly active antiretroviral therapy er: data from the HIV Atlanta cohort study. Clin Infect Dis. 2004;39:1507-13.
47. Vallet-Pichard A, Pol S. Natural History and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol. 2006;44:28-34.
48. Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis uin HIV-hepatitis C virus-coinfected patients? Clin Infect Dis. 2006;42:26-70.
49. Alberti A, Cumeck N, Collins S, Gerlich W, Lundgren J, Palù G, et al. (The ECC Jury). Short Statement of the First European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-Infected Patients. J Hepatol. 2005;42:615-24.
50. Torriani FJ, Rodríguez-Torres M, Rockstroch JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. for the APRICOT Study Group. Peginterferon alfa-2a plus Ribavirin for Chronic hepatitis C Virus infection in HIV-Infected Patients. N Engl J Med. 2004;351:438-50.
51. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. for the ANRS HC02 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b plus ribavirina, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA. 2004;292: 2839-48.
52. Chung RT, Andersen J, Volperding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirina for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-9.
53. Hepatitis C. New Drugs Pipeline. Drugs specifics for Hepatitis C. Disponible en: http://www.frontiemet.net/~monty/hcvpipel.html. Visitado el 11 de abril de 2006.